Overview

NCI Definition: A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/ or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis. [1]

Significant Genes in Triple-Hit Lymphoma

AFF1 +

ALK +

BCL2 +

BCL6 +

ELL +

FGFR3 +

IGH +

IRF4 +

KMT2A +

MAF +

MAFB +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MYC +

NRIP3 +

WHSC1 +

Disease Details

Synonyms
High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Triple Hit Lymphoma, High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
Parent(s)
High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.